Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 14/20 | 0.56 |
| ▸ | GRIK2 | Q13002 | 10/20 | 0.56 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.56 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.56 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.53 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.53 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.53 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 5/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 5/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25660325 | 1.00 | GRIK1 (0.56) | GRIK1GRIK2GRM1GRM2GRIA4 | |
| SCHEMBL11184651 | 0.79 | GRIK1 (0.58) | GRIK1GRIK2GRM1GRM2GRIA4 | |
| SCHEMBL11184653 | 0.79 | GRIK1 (0.58) | GRIK1GRIK2GRM1GRM2GRIA4 | |
| SCHEMBL25008057 | 0.77 | CA1 (0.33) | GRIK1GRIK2GRM1GRM2GRIA4 | |
| SCHEMBL3617857 | 0.76 | — | — | |
| SCHEMBL1226498 | 0.76 | GRIK1 (0.57) | GRIK1GRIK2GRM1GRM2GRIA4 | |
| Aspartic Acid SCHEMBL135731 | 0.76 | GRIK1 (0.57) | GRIK1GRIK2GRM1GRM2GRIA4 | |
| SCHEMBL1226497 | 0.76 | GRIK1 (0.57) | GRIK1GRIK2GRM1GRM2GRIA4 | |
| SCHEMBL3508713 | 0.76 | — | — | |
| SCHEMBL24046735 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | PAICS, LNPEP, DNPEP | GRIK1 2914/4885GRIK2 3197/4885GRM1 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.